Umeclidinium bromide

Umeclidinium bromide, sold under the brand name Incruse Ellipta among others, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive [pulmonary disease]. It is also approved for this indication in combination with vilanterol, and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.
It is on the WHO Model [List of Essential Medicines|World Health Organization's List of Essential Medicines]. In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1million prescriptions.